Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation

Cancer Research

Volumn 68, Issue 24, 2008, Pages 10205-10214

  Dissanayake, Samudra K ^a   Olkhanud, Purevdorj B ^a   O'Connell, Michael P ^a   Carter, Arnell ^a   French, Amanda D ^a   Camilli, Tura C ^a   Emeche, Chineye D ^a   Hewitt, Kyle J ^a   Rosenthal, Devin T ^a   Leotlela, Poloko D ^a   Wade, Michael S ^a   Yang, Sherry W ^a   Brant, Larry ^a   Nickoloff, Brian J ^b   Messina, Jane L ^c   Biragyn, Arya ^a   Hoek, Keith S ^d   Taub, Dennis D ^a   Longo, Dan L ^a   Sondak, Vernon K ^c   Hewitt, Stephen M ^e   Weeraratna, Ashani T ^a,f   more..

^a NATIONAL INSTITUTE ON AGING   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN RECOGNIZED BY T CELLS 1; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR SOX10; UNCLASSIFIED DRUG; WNT5A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENZYME ACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHOSPHORYLATION; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; TRANSFECTION; WNT PROTEINS;

EID: 57749098673     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2149     Document Type: Article

References (38)

1. Dissanayake SK, Thompson JA, Bosch JJ, et al. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004;64:1867-74.
2. Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. Engineering T cells for cancer therapy. Br J Cancer 2005;93:1085-91.
3. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res 2006;4:218-27.
4. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer Regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
5. Hoek KS, Schlegel NC, Brafford P, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006;19:290-302.
6. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
7. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002;1:279-88.
8. Dissanayake SK, Wade M, Johnson CE, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007;282:17259-71.
9. Kuhl M, Sheldahl LC, Malbon CC, Moon RT. Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J Biol Chem 2000;275:12701-11.
10. Zehn D, Cohen CJ, Reiter Y, Walden P. Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming. Int Immunol 2006;18:1647-54.
11. Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol 1997;14:173-92.
12. Skipper JC, Gulden PH, Hendrickson RC, et al. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer 1999;82:669-77.
13. Weeraratna AT, Becker D, Carr KM, et al. Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 2004;23:2264-74.
14. Leotlela PD, Wade MS, Duray PH, et al. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 2007;26:3846-56.
15. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006;66:8878-86.
16. Zhao Y, Zheng Z, Cohen CJ, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 2006;13:151-9.
17. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1985. NIH publication number 86-23.
18. Schiavo R, Baatar D, Olkhanud P, et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006;107:4597-605.
19. Murisier F, Beermann F. Genetics of pigment cells: lessons from the tyrosinase gene family. Histol Histopathol 2006;21:567-78.
20. Kamaraju AK, Bertolotto C, Chebath J, Revel M. Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. J Biol Chem 2002;277:15132-41.
21. Gartsbein M, Alt A, Hashimoto K, Nakajima K, Kuroki T, Tennenbaum T. The role of protein kinase C δ activation and STAT3 Ser727 phosphorylation in insulin-induced keratinocyte proliferation. J Cell Sci 2006;119:470-81.
22. Sheldahl LC, Park M, Malbon CC, Moon RT. Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr Biol 1999;9:695-8.
23. Rebhun RB, Lazar AJ, Fidler IJ, Gershenwald JE. Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Metastasis 2008;25:191-9.
24. Chao C, Martin RC II, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004;11:259-64.
25. Wolf K, Mazo I, Leung H, et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003;160:267-77.
26. Wong SY, Hynes RO. Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 2006;5:812-7.
27. Sosman JA, Weeraratna AT, Sondak VK. When will melanoma vaccines be proven effective? J Clin Oncol 2004;22:387-9.
28. Zuidervaart W, Pavey S, van Nieuwpoort FA, et al. Expression of Wnt5a and its downstream effector β-catenin in uveal melanoma. Melanoma Res 2007;17:380-6.
29. Berset M, Cerottini JP, Guggisberg D, et al. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer 2001;95:73-7.
30. Aziz MH, Manoharan HT, Church DR, et al. Protein kinase C (varε) interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res 2007;67:8828-38.
31. Park YJ, Park ES, Kim MS, et al. Involvement of the protein kinase C pathway in thyrotropin-induced STAT3 activation in FRTL-5 thyroid cells. Mol Cell Endocrinol 2002;194:77-84.
32. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
33. Xie TX, Huang FJ, Aldape KD, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006;66:3188-96.
34. Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004;173:3844-54.
35. Sen M, Chamorro M, Reifert J, Corr M, Carson DA. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum 2001;44:772-81.
36. Katoh M. STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chouronic persistent inflammation, rheumatoid arthritis and cancer (Review). Int J Mol Med 2007;19:273-8.
37. Topol L, Jiang X, Choi H, et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3 independent β-catenin degradation. J Cell Biol 2003;162:899-908.
38. Westfall TA, Brimeyer R, Twedt J, et al. Wnt5/pipetail functions in vertebrate axis formation as a negative regulator of Wnt/ β-catenin activity. J Cell Biol 2003;162:889-98.